Mannitol treatment is not effective in therapy of rabies virus infection in mice.
Blood–brain barrier
Mannitol
Rabies
Therapy
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
02 08 2019
02 08 2019
Historique:
received:
15
08
2017
revised:
29
11
2017
accepted:
11
12
2017
pubmed:
25
12
2017
medline:
28
7
2020
entrez:
25
12
2017
Statut:
ppublish
Résumé
Rabies is a deadly viral disease with an extremely high fatality rate in humans. Previously, it was suggested that an enhancement of the blood-brain barrier (BBB) permeability, which allows immune cells and/or antibodies to enter the central nervous system (CNS) tissue, is critical to clear the infection. In this study, we utilised mannitol to increase BBB permeability in mice infected with highly pathogenic silver-haired bat rabies virus (SHBRV). We found that intraperitoneal injection of mannitol causes a slight, transient increase of BBB permeability in the treated mice. SHBRV-infected mice were treated with intraperitoneally administered mannitol daily from day 3 or day 4 post-infection, but no effect of this treatment on the time of disease onset, clinical signs or survival was observed. This data indicates that the increase of BBB permeability by mannitol is not efficient in promoting CNS virus clearance in SHBRV-infected mice.
Identifiants
pubmed: 29274698
pii: S0264-410X(17)31781-4
doi: 10.1016/j.vaccine.2017.12.028
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
Mannitol
3OWL53L36A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4710-4714Informations de copyright
Copyright © 2017 Elsevier Ltd. All rights reserved.